1
|
Cheng Z, Fobian SF, Gurrieri E, Amin M, D'Agostino VG, Falahati M, Zalba S, Debets R, Garrido MJ, Saeed M, Seynhaeve ALB, Balcioglu HE, Ten Hagen TLM. Lipid-based nanosystems: the next generation of cancer immune therapy. J Hematol Oncol 2024; 17:53. [PMID: 39030582 PMCID: PMC11265205 DOI: 10.1186/s13045-024-01574-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2024] [Accepted: 07/11/2024] [Indexed: 07/21/2024] Open
Abstract
Immunotherapy has become an important part of the oncotherapy arsenal. Its applicability in various cancer types is impressive, as well as its use of endogenous mechanisms to achieve desired ends. However, off-target or on-target-off-tumor toxicity, limited activity, lack of control in combination treatments and, especially for solid tumors, low local accumulation, have collectively limited clinical use thereof. These limitations are partially alleviated by delivery systems. Lipid-based nanoparticles (NPs) have emerged as revolutionary carriers due to favorable physicochemical characteristics, with specific applications and strengths particularly useful in immunotherapeutic agent delivery. The aim of this review is to highlight the challenges faced by immunotherapy and how lipid-based NPs have been, and may be further utilized to address such challenges. We discuss recent fundamental and clinical applications of NPs in a range of areas and provide a detailed discussion of the main obstacles in immune checkpoint inhibition therapies, adoptive cellular therapies, and cytokine therapies. We highlight how lipid-based nanosystems could address these through either delivery, direct modulation of the immune system, or targeting of the immunosuppressive tumor microenvironment. We explore advanced and emerging liposomal and lipid nanoparticle (LNP) systems for nucleic acid delivery, intrinsic and extrinsic stimulus-responsive formulations, and biomimetic lipid-based nanosystems in immunotherapy. Finally, we discuss the key challenges relating to the clinical use of lipid-based NP immunotherapies, suggesting future research directions for the near term to realize the potential of these innovative lipid-based nanosystems, as they become the crucial steppingstone towards the necessary enhancement of the efficacy of immunotherapy.
Collapse
Affiliation(s)
- Ziyun Cheng
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
- Nanomedicine Innovation Center Erasmus (NICE), Erasmus Medical Center, Rotterdam, The Netherlands
| | - Seth-Frerich Fobian
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
- Nanomedicine Innovation Center Erasmus (NICE), Erasmus Medical Center, Rotterdam, The Netherlands
| | - Elena Gurrieri
- Laboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy
| | - Mohamadreza Amin
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
- Nanomedicine Innovation Center Erasmus (NICE), Erasmus Medical Center, Rotterdam, The Netherlands
| | - Vito Giuseppe D'Agostino
- Laboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy
| | - Mojtaba Falahati
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Sara Zalba
- Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Navarra Institute for Health Research, Pamplona, Spain
| | - Reno Debets
- Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - María J Garrido
- Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Navarra Institute for Health Research, Pamplona, Spain
| | - Mesha Saeed
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Ann L B Seynhaeve
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Hayri E Balcioglu
- Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
| | - Timo L M Ten Hagen
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
- Nanomedicine Innovation Center Erasmus (NICE), Erasmus Medical Center, Rotterdam, The Netherlands.
| |
Collapse
|
2
|
Shimizu T, Lila ASA, Kitayama Y, Abe R, Takata H, Ando H, Ishima Y, Ishida T. Peritoneal B Cells Play a Role in the Production of Anti-polyethylene Glycol (PEG) IgM against Intravenously Injected siRNA-PEGylated Liposome Complexes. Biol Pharm Bull 2024; 47:469-477. [PMID: 38383000 DOI: 10.1248/bpb.b23-00733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2024]
Abstract
Polyethylene glycol (PEG)-modified (PEGylated) cationic liposomes are frequently used as delivery vehicles for small interfering RNA (siRNA)-based drugs because of their ability to encapsulate/complex with siRNA and prolong the circulation half-life in vivo. Nevertheless, we have reported that subsequent intravenous (IV) injections of siRNA complexed with PEGylated cationic liposomes (PLpx) induces the production of anti-PEG immunoglobulin M (IgM), which accelerates the blood clearance of subsequent doses of PLpx and other PEGylated products. In this study, it is interesting that splenectomy (removal of spleen) did not prevent anti-PEG IgM induction by IV injection of PLpx. This indicates that B cells other than the splenic version are involved in anti-PEG IgM production under these conditions. In vitro and in vivo studies have shown that peritoneal cells also secrete anti-PEG IgM in response to the administration of PLpx. Interleukin-6 (IL-6) is a glycoprotein that is secreted by peritoneal immune cells and has been detected in response to the in vivo administration of PLpx. These observations indicate that IV injection of PLpx stimulates the proliferation/differentiation of peritoneal PEG-specific B cells into plasma cells via IL-6 induction, which results in the production of anti-PEG IgM from the peritoneal cavity of mice. Our results suggest the mutual contribution of peritoneal B cells as a potent anti-PEG immune response against PLpx.
Collapse
Affiliation(s)
- Taro Shimizu
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Amr S Abu Lila
- Department of Pharmaceutics, College of Pharmacy, Hail University
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University
| | - Yuka Kitayama
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Ryo Abe
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Haruka Takata
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Hidenori Ando
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Yu Ishima
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Tatsuhiro Ishida
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| |
Collapse
|
3
|
Yoshie K, Ishihara K. [Solubilization of Poorly Water-soluble Drugs with Amphiphilic Phospholipid Polymers]. YAKUGAKU ZASSHI 2023; 143:745-756. [PMID: 37661440 DOI: 10.1248/yakushi.23-00023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
Most drug candidates developed in recent years are poorly water-soluble, which is a key challenge in pharmaceutical science. Various solubilization methods have been investigated thus far, most of which require solubilizers that provide a local hydrophobic environment wherein a drug can dissolve or induce interactions with drug molecules. We have focused on amphiphilic 2-methacryloyloxyethyl phosphoryl choline (MPC) polymers. In addition to the ease of molecular design of amphiphilic MPC polymers owing to their chemical structures, they have been reported to possess high biocompatibility in various biomaterial applications. Additionally, amphiphilic MPC polymers have been applied in the pharmaceutical field, especially in solubilization. We have qualitatively and quantitatively evaluated the effects of the chemical structure and physical properties of the solubilizer on the MPC polymers. In particular, MPC polymers with different chemical structures were designed and synthesized. The inner polarity and molecular mobility in the polymer aggregates were evaluated, indicating that the intrinsic properties reflect the chemical structure of the polymer. Additionally, amphiphilic MPC polymers were used to improve the solubility of poorly water-soluble drugs and as solid dispersion carriers, and they exhibited superior solubilizing abilities compared to a commonly used polymer. Furthermore, the solubility of biopharmaceuticals, such as peptides, was improved. It is possible to design and synthesize optimal structures based on the polarity of the hydrophobic environment and the intermolecular interaction with a drug. This research provides a unified interpretation of drugs and efficiently summarizes knowledge about drug development, which will facilitate the efficient and rapid development of drug formulations.
Collapse
Affiliation(s)
- Kensuke Yoshie
- Formulation Technology Research Laboratories, Daiichi Sankyo., Ltd
| | - Kazuhiko Ishihara
- Department of Materials Engineering, School of Engineering, The University of Tokyo
- Division of Materials and Manufacturing Science, School of Engineering, Osaka University
| |
Collapse
|
4
|
Wu T, Yan D, Hou W, Jiang H, Wu M, Wang Y, Chen G, Tang C, Wang Y, Xu H. Biomimetic Red Blood Cell Membrane-Mediated Nanodrugs Loading Ursolic Acid for Targeting NSCLC Therapy. Cancers (Basel) 2022; 14:cancers14184520. [PMID: 36139680 PMCID: PMC9496832 DOI: 10.3390/cancers14184520] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Revised: 09/03/2022] [Accepted: 09/05/2022] [Indexed: 11/16/2022] Open
Abstract
Simple Summary Lung cancer is the second most common cancer after breast cancer. Non-small-cell lung cancer, which represents more than 85% of all lung cancer subtypes, is known for its tumor progression and metastasis, resulting in poor clinical outcomes. Conventional therapies for NSCLC, such as surgery, chemotherapy, and radiotherapy, always fail due to therapeutic resistance. In recent years, ursolic acid (UA), a natural pentacyclic triterpenoid compound, has been shown to be a promising antitumor drug by regulating multiple signaling pathways in cancers. Unfortunately, the poor water solubility, low bioavailability, and systemic toxicity of UA limit its clinical application. In this study, a biomimetic red blood cell membrane nanocarrier was developed to deliver UA to targeted tumor sites efficiently, and it inhibited tumor growth by inducing the apoptosis and autophagy of cancer cells both in vitro and in vivo. Abstract As one of the most common cancers worldwide, non-small-cell lung cancer (NSCLC) treatment always fails owing to the tumor microenvironment and resistance. UA, a traditional Chinese medicine, was reported to have antitumor potential in tumor models in vitro and in vivo, but showed impressive results in its potential application for poor water solubility. In this study, a novel biomimetic drug-delivery system based on UA-loaded nanoparticles (UaNPs) with a red blood cell membrane (RBCM) coating was developed. The RBCM-coated UANPs (UMNPs) exhibited improved water solubility, high stability, good biosafety, and efficient tumor accumulation. Importantly, the excellent antitumor efficiency of the UMNPs was confirmed both in vitro and in vivo in cancer models. In addition, we further investigated the antitumor mechanism of UMNPs. The results of Western blotting showed that UMNPs exerted an anticancer effect by inducing the apoptosis and autophagy of NSCLC cells, which makes it superior to free UA. In addition, body weight monitoring, hematoxylin and eosin (HE) analysis, and immunohistochemical (IHC) analysis showed no significant difference between UMNPs and the control group, indicating the safety of UMNPs. Altogether, the preparation of biomimetic UMNPs provides a promising strategy to improve outcomes in NSCLC.
Collapse
Affiliation(s)
- Ting Wu
- Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Nanjing 210009, China
- Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211116, China
| | - Dan Yan
- Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211116, China
| | - Wenjun Hou
- Department of Dermatology, Drum Tower Hospital of Medical School, Nanjing University, Nanjing 211116, China
| | - Hui Jiang
- Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211116, China
| | - Min Wu
- Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211116, China
| | - Yanling Wang
- Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211116, China
| | - Gang Chen
- Department of Gastrointestinal Surgery, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211199, China
| | - Chunming Tang
- Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211116, China
| | - Yijun Wang
- Department of Pharmacy, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 211116, China
- Correspondence: (Y.W.); (H.X.)
| | - Huae Xu
- Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Nanjing 210009, China
- Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211116, China
- Correspondence: (Y.W.); (H.X.)
| |
Collapse
|
5
|
Wang XD, Yu WJ, Liu JH, Du J, Chen KN, Hu QQ, Sun WL, Ying GQ. Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor. Front Bioeng Biotechnol 2022; 10:923059. [PMID: 35677307 PMCID: PMC9168434 DOI: 10.3389/fbioe.2022.923059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 05/05/2022] [Indexed: 11/13/2022] Open
Abstract
The clinical use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) is limited by its short serum half-life. In this study, a long-acting strategy for site-specific modification of rhG-CSF with 1-pentadecyl-1H-pyrrole-2,5-dione (C15 fatty chain-maleimide, C15-MAL) was studied in mixed DMSO-aqueous solutions. The factors influencing the conjugation reaction were investigated and optimized, and a high yield of the desired product (C15-rhG-CSF) was achieved. Subsequently, C15-rhG-CSF product was efficiently purified using preparative liquid chromatography, and further characterized. Circular dichroism spectroscopy analysis showed that the secondary structure of C15-rhG-CSF had no significant difference from unmodified rhG-CSF. C15-rhG-CSF retained 87.2% of in vitro bioactivity of unmodified rhG-CSF. The pharmacokinetic study showed that the serum half-life of C15-rhG-CSF in mice was 2.08-fold longer than that of unmodified rhG-CSF. Furthermore, C15-rhG-CSF by single-dose subcutaneous administration showed better in vivo efficacy than those of both PEG10k-rhG-CSF by single-dose administration and rhG-CSF by multiple doses administration. This study demonstrated the potential of C15-rhG-CSF being developed into a novel drug candidate as well as an efficient process for the development of long-acting protein and peptide drugs.
Collapse
Affiliation(s)
- Xu-Dong Wang
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
- *Correspondence: Xu-Dong Wang, ; Wen-Long Sun, ; Guo-Qing Ying,
| | - Wei-Jia Yu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Jia-Hui Liu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Jie Du
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Kang-Nan Chen
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Qin-Qin Hu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
| | - Wen-Long Sun
- Institute of Biomedical Research, School of Life Sciences, Shandong University of Technology, Zibo, China
- *Correspondence: Xu-Dong Wang, ; Wen-Long Sun, ; Guo-Qing Ying,
| | - Guo-Qing Ying
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China
- *Correspondence: Xu-Dong Wang, ; Wen-Long Sun, ; Guo-Qing Ying,
| |
Collapse
|
6
|
Shimizu T, Kawaguchi Y, Ando H, Ishima Y, Ishida T. Development of an Antigen Delivery System for a B Cell-Targeted Vaccine as an Alternative to Dendritic Cell-Targeted Vaccines. Chem Pharm Bull (Tokyo) 2022; 70:341-350. [DOI: 10.1248/cpb.c22-00047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Taro Shimizu
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Yoshino Kawaguchi
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Hidenori Ando
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Yu Ishima
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| | - Tatsuhiro Ishida
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
| |
Collapse
|
7
|
Guamba E, Cevallos A. Recent advances on the development of a universal blood type. BIONATURA 2022. [DOI: 10.21931/rb/2022.07.01.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Blood transfusion is the most common form of tissue transplant, and correct blood type matching is decisive for the success of this procedure. However, the availability of different blood types depends on each population, leading to a shortage of blood units from uncommon types. Then, it represents a problem for patients who need a blood transfusion because the supply for their blood type is scarce. Fortunately, researchers have been developing different techniques to engineer universal red blood cells (RBC) that could be transplanted to any human being independent of its blood type. This paper details the main features of blood transfusion and red blood cells maintenance and the two more recent procedures used to produce universal RBCs, the Enzymatically Converted Group O (ECO) and the antigen masking methods.
Collapse
Affiliation(s)
- Esteban Guamba
- Yachay Tech University, School of Biological Sciences and engineering, Hda. San José s/n y Proyecto Yachay, 100119, Urcuquí, Ecuador
| | - Alejandra Cevallos
- Yachay Tech University, School of Biological Sciences and engineering, Hda. San José s/n y Proyecto Yachay, 100119, Urcuquí, Ecuador
| |
Collapse
|
8
|
Khatoon N, Zhang Z, Zhou C, Chu M. Macrophage membrane coated nanoparticles: a biomimetic approach for enhanced and targeted delivery. Biomater Sci 2022; 10:1193-1208. [DOI: 10.1039/d1bm01664d] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The enhanced and targeted drug delivery with low systemic toxicity and subsequent release of drugs is the major concern among researchers and pharmaceutics. Inspite of greater advancement and discoveries in...
Collapse
|
9
|
Yoshie K, Yada S, Ando S, Ishihara K. Effects of inner polarity and viscosity of amphiphilic phospholipid polymer aggregates on the solubility enhancement of poorly water-soluble drugs. Colloids Surf B Biointerfaces 2020; 195:111215. [DOI: 10.1016/j.colsurfb.2020.111215] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 06/22/2020] [Accepted: 06/23/2020] [Indexed: 02/05/2023]
|
10
|
Bivi N, Swearingen CA, Shockley TE, Sloan JH, Pottanat TG, Carter QL, Hodsdon ME, Siegel RW, Konrad RJ. Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity. J Immunol Methods 2020; 486:112856. [PMID: 32916164 DOI: 10.1016/j.jim.2020.112856] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 07/20/2020] [Accepted: 09/02/2020] [Indexed: 11/16/2022]
Abstract
Polyethylene glycol (PEG) represents an effective strategy to improve the pharmacokinetic profile of a molecule as it extends the biotherapeutic's half-life, masks immunogenic epitopes or modifies its distribution. The addition of one or multiple PEG moieties, in either linear or branched form, is known to carry the risk of potentially inducing an immunogenic response against PEG. The importance of accurately quantifying anti-PEG antibodies during a clinical study is well recognized and stems from the fact that anti-PEG antibodies have been shown to negatively impact the efficacy of the biotherapeutic that the PEG is coupled to. As a consequence, sponsors are encouraged to develop immunogenicity assays to assess appropriately the presence of anti-drug antibodies (ADA) against the protein component as well as the PEG. However, detection of anti-PEG antibodies is complicated by a number of technical challenges, including the availability of appropriate positive control material. In addition, the fact that some anti-PEG antibodies are known to circulate as low-affinity IgM, drives the need for an assay able to detect low affinity anti-PEG ADA even in the presence of high concentrations of the biotherapeutic. To address this need, we developed and validated an Affinity Capture Elution (ACE)-AGL assay to detect anti-drug and anti-PEG antibodies. In this assay, which we call ACE-AGL, ADA are captured by biotin-PEG-drug, acid eluted and re-captured on a second plate coated with protein AGL. ADA are then detected using Ruthenium-PEG-drug. The new assay format described is highly sensitive to both anti-drug and anti-PEG antibodies and very drug-tolerant. The ACE-AGL assay is easy to perform and has been successfully validated at two separate CROs. We propose the ACE-AGL format as a valid and effective alternative to the currently available assay methods.
Collapse
Affiliation(s)
- Nicoletta Bivi
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America.
| | - Craig A Swearingen
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| | - Travis E Shockley
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| | - John H Sloan
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| | - Thomas G Pottanat
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| | - Quincy Lasha Carter
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| | - Michael E Hodsdon
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| | - Robert W Siegel
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| | - Robert J Konrad
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
| |
Collapse
|
11
|
Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev 2020; 154-155:163-175. [PMID: 32745496 DOI: 10.1016/j.addr.2020.07.024] [Citation(s) in RCA: 294] [Impact Index Per Article: 73.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 07/28/2020] [Accepted: 07/29/2020] [Indexed: 12/20/2022]
Abstract
Conjugation of polyethylene glycols (PEGs) to proteins or drug delivery nanosystems is a widely accepted method to increase the therapeutic index of complex nano-biopharmaceuticals. Nevertheless, these drugs and agents are often immunogenic, triggering the rise of anti-drug antibodies (ADAs). Among these ADAs, anti-PEG IgG and IgM were shown to account for efficacy loss due to accelerated blood clearance of the drug (ABC phenomenon) and hypersensitivity reactions (HSRs) entailing severe allergic symptoms with occasionally fatal anaphylaxis. In addition to recapitulating the basic information on PEG and its applications, this review expands on the physicochemical factors influencing its immunogenicity, the prevalence, features, mechanism of formation and detection of anti-PEG IgG and IgM and the mechanisms by which these antibodies (Abs) induce ABC and HSRs. In particular, we highlight the in vitro, animal and human data attesting to anti-PEG Ab-induced complement (C) activation as common underlying cause of both adverse effects. A main message is that correct measurement of anti-PEG Abs and individual proneness for C activation might predict the rise of adverse immune reactions to PEGylated drugs and thereby increase their efficacy and safety.
Collapse
Affiliation(s)
- Gergely Tibor Kozma
- Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University Medical School, Budapest, Hungary; SeroScience Ltd, Budapest, Hungary
| | - Taro Shimizu
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan
| | - Tatsuhiro Ishida
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan
| | - Janos Szebeni
- Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University Medical School, Budapest, Hungary; SeroScience Ltd, Budapest, Hungary; Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, Miskolc University, Miskolc, Hungary.
| |
Collapse
|
12
|
Ehlinger C, Spear N, Doddareddy R, Shankar G, Schantz A. A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum. J Immunol Methods 2019; 474:112669. [PMID: 31614128 DOI: 10.1016/j.jim.2019.112669] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 08/29/2019] [Accepted: 09/12/2019] [Indexed: 12/31/2022]
Abstract
Detection of anti-drug antibodies is a critical step in the development of large molecule biopharmaceuticals. In the case of multicomponent/multifunctional molecules, such as fusion proteins and protein conjugates such as covalent polyethylene glycol (PEG)~protein conjugates, it is useful to further characterize anti-drug antibody (ADA) binding to key domains of the drug. The detection of anti-PEG antibodies poses special challenges that if overlooked can result in underreporting antibody responses. Here we describe the development and characterization of a novel ELISA to detect anti-PEG antibodies that provides a more complete interpretation of anti-PEG than other published methods. Being specific to the PEG moiety alone, this method is intended to detect anti-PEG antibodies independent of the protein to which PEG is conjugated. Based upon early indications that our assay could detect anti-PEG antibodies at a surprisingly high frequency in the general population, our emphasis throughout method development and validation was to ensure that non-specific signals and unintended interactions were not falsely contributing to detection of anti-PEG antibodies. Techniques, including orthogonal methods used to ensure that this ELISA detected antibodies specific to PEG included competition, immunodepletion, immunoprecipitation/western blot and an Octet kinetic binding analysis. The validated ELISA can detect 100 ng/mL of an anti-PEG IgG positive control and 800 ng/mL of an anti-PEG IgM positive control in the presence of 7.5 μg/mL of the PEGylated therapeutic (MW 64 kDa). The intra-assay percent co-efficient of variation (CV) and inter-assay CV of the low positive control samples in the screening method were 4.1 to 7.2% and 16.7 to 17.7%, respectively. Additional assay performance parameters that were validated are also described. When the validated assay was applied to a population of 200 healthy blood donors with no known exposure to biopharmaceutical PEG conjugates it indicated a pre-existing anti-PEG antibody prevalence of 97.5%. We suggest this surprising result is a consequence of exposure to PEG additives in everyday products, such as cosmetics, processed foods and over-the-counter (OTC) pharmaceuticals.
Collapse
Affiliation(s)
- Christopher Ehlinger
- Biologics Development Sciences, Janssen BioTherapeutics, Janssen R&D, LLC, 1400 McKean Road, PO Box 776, Spring House, PA 19477, USA.
| | - Nathan Spear
- Biologics Development Sciences, Janssen BioTherapeutics, Janssen R&D, LLC, 1400 McKean Road, PO Box 776, Spring House, PA 19477, USA
| | - Rajitha Doddareddy
- Biologics Development Sciences, Janssen BioTherapeutics, Janssen R&D, LLC, 1400 McKean Road, PO Box 776, Spring House, PA 19477, USA
| | - Gopi Shankar
- Biologics Development Sciences, Janssen BioTherapeutics, Janssen R&D, LLC, 1400 McKean Road, PO Box 776, Spring House, PA 19477, USA
| | - Allen Schantz
- Biologics Development Sciences, Janssen BioTherapeutics, Janssen R&D, LLC, 1400 McKean Road, PO Box 776, Spring House, PA 19477, USA
| |
Collapse
|
13
|
Kozma GT, Mészáros T, Vashegyi I, Fülöp T, Örfi E, Dézsi L, Rosivall L, Bavli Y, Urbanics R, Mollnes TE, Barenholz Y, Szebeni J. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions. ACS NANO 2019; 13:9315-9324. [PMID: 31348638 DOI: 10.1021/acsnano.9b03942] [Citation(s) in RCA: 117] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
Polyethylene glycol (PEG)-coated nanopharmaceuticals can cause mild to severe hypersensitivity reactions (HSRs), which can occasionally be life threatening or even lethal. The phenomenon represents an unsolved immune barrier to the use of these drugs, yet its mechanism is poorly understood. This study showed that a single i.v. injection in pigs of a low dose of PEGylated liposomes (Doxebo) induced a massive rise of anti-PEG IgM in blood, peaking at days 7-9 and declining over 6 weeks. Bolus injections of PEG-liposomes during seroconversion resulted in anaphylactoid shock (pseudo-anaphylaxis) within 2-3 min, although similar treatments of naı̈ve animals led to only mild hemodynamic disturbance. Parallel measurement of pulmonary arterial pressure (PAP) and sC5b-9 in blood, taken as measures of HSR and complement activation, respectively, showed a concordant rise of the two variables within 3 min and a decline within 15 min, suggesting a causal relationship between complement activation and pulmonary hypertension. We also observed a rapid decline of anti-PEG IgM in the blood within minutes, increased binding of PEGylated liposomes to IgM+ B cells in the spleen of immunized animals compared to control, and increased C3 conversion by PEGylated liposomes in the serum of immunized pigs. These observations taken together suggest rapid binding of anti-PEG IgM to PEGylated liposomes, leading to complement activation via the classical pathway, entailing anaphylactoid shock and accelerated blood clearance of liposome-IgM complexes. These data suggest that complement activation plays a causal role in severe HSRs to PEGylated nanomedicines and that pigs can be used as a hazard identification model to assess the risk of HSRs in preclinical safety studies.
Collapse
Affiliation(s)
- Gergely Tibor Kozma
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
- SeroScience Ltd. , Budapest 1125, Hungary, and Cambridge , Massachusetts 02138 , United States
| | - Tamás Mészáros
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
| | - Ildikó Vashegyi
- SeroScience Ltd. , Budapest 1125, Hungary, and Cambridge , Massachusetts 02138 , United States
| | - Tamás Fülöp
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
| | - Erik Örfi
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
| | - László Dézsi
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
| | - László Rosivall
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
- SeroScience Ltd. , Budapest 1125, Hungary, and Cambridge , Massachusetts 02138 , United States
- Department of Pathophysiology, International Nephrology Research and Training Center , Semmelweis University , Budapest 1089 , Hungary
| | - Yaelle Bavli
- Laboratory of Membrane and Liposome Research, IMRIC , Hebrew University-Hadassah Medical School , Jerusalem 9112102 , Israel
| | - Rudolf Urbanics
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
- SeroScience Ltd. , Budapest 1125, Hungary, and Cambridge , Massachusetts 02138 , United States
| | - Tom Eirik Mollnes
- Department of Immunology , Oslo University Hospital , Rikshospitalet , Oslo 0372 , Norway
- Research Laboratory, Nordland Hospital Bodø, and Faculty of Health Sciences and TREC , University of Tromsø , Tromsø 9019 , Norway
- Centre of Molecular Inflammation Research , Norwegian University of Science and Technology , Trondheim 7012 , Norway
| | - Yechezkel Barenholz
- Laboratory of Membrane and Liposome Research, IMRIC , Hebrew University-Hadassah Medical School , Jerusalem 9112102 , Israel
| | - János Szebeni
- Nanomedicine Research and Education Center , Semmelweis University , Budapest 1089 , Hungary
- SeroScience Ltd. , Budapest 1125, Hungary, and Cambridge , Massachusetts 02138 , United States
- Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health , Miskolc University , Miskolc 3515 , Hungary
| |
Collapse
|
14
|
Shiraishi K, Yokoyama M. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS 2019; 20:324-336. [PMID: 31068982 PMCID: PMC6493319 DOI: 10.1080/14686996.2019.1590126] [Citation(s) in RCA: 120] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 03/01/2019] [Accepted: 03/01/2019] [Indexed: 05/02/2023]
Abstract
Polymeric-micelle carrier systems have emerged as a novel drug-carrier system and have been actively studied for anticancer drug targeting. In contrast, toxicological and immunological concerns related to not only polymeric-micelle carrier systems, but also other nanocarrier systems, have received little attention owing to researchers' focus on therapeutic effects. However, in recent clinical contexts, biopharmaceuticals' effects on immune responses have come to light, requiring that researchers substantively explore the potential negative side effects of nanocarrier systems and of therapeutic proteins in order to develop nanocarrier systems suitable for clinical use. The present review describes current insights into both toxicological and immunological issues regarding polymeric-micelle carrier systems. The review focuses on immunogenicity issues of polymeric-micelle carrier systems possessing poly(ethylene glycol) (PEG). We conclude that PEG-related immunogenicity is deeply related to characteristics of a counterpart block of PEG-conjugates, and we propose future directions for addressing this unresolved issue.
Collapse
Affiliation(s)
- Kouichi Shiraishi
- Division of Medical Engineering, Research Center for Medical Sciences, The Jikei University School of Medicine, Kashiwa, Chiba, Japan
| | - Masayuki Yokoyama
- Division of Medical Engineering, Research Center for Medical Sciences, The Jikei University School of Medicine, Kashiwa, Chiba, Japan
| |
Collapse
|